• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Singapore·Financial Services·U10.SI
Share

UOB-Kay Hian Holdings Limited Stocks

SGD 2.99Last Updated 17.11.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

SGD 2.36B

SGD 2.99
Key Takeaways

Risk factor

Considerable default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

UOB-Kay Hian Holdings Limited, established in Singapore in 2000, operates as an investment holding company offering a broad array of financial services to institutions, large corporations, high-net-worth individuals, and retail investors. The company's reach extends across Singapore, Hong Kong, Thailand, Malaysia, and other international markets. Its core activities encompass stockbroking, futures broking, structured lending, proprietary investment trading, and margin financing, complemented by nominee and research services. UOB-Kay Hian also provides comprehensive corporate finance solutions, including financial advisory, investment banking, underwriting, and placement services for both initial public offerings and secondary market transactions. Furthermore, the firm acts as a financier and arranger for principals acquiring strategic interests in publicly listed companies regionally. Additional services include investor education, structured financing arrangements like privatization funding and credit restructuring, and a full suite of wealth management offerings such as asset allocation strategies, discretionary portfolio management, asset manager platforms, and external investment products. The product offerings span equities, bonds, contracts for difference (CFDs), daily leverage certificates (DLCs), exchange-traded funds (ETFs), futures and options, leveraged foreign exchange, advisory services, and unit trusts. Originally known as Kay Hian Holdings Ltd., the company adopted its current name in October 2000.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of U10.SI is 5.00 and suggests 63.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.11.2026 20:55

A Restaurant Owner Without a Contract with Guests: An Investor Says Anthropic’s Main Risk Isn’t a Loss

17.11.2026 19:28

"The Neoclouds Are in Big Trouble": Steve Eisman Names the Main Victims of the Nvidia Scandal

17.11.2026 19:28

Anthropic to Price IPO Shares at the Top of the Range — Bloomberg

17.11.2026 19:10

Anthropic received a "buy" recommendation ahead of its IPO. What convinced the analyst?

17.11.2026 18:44

Shares of a biotech company backed by AstraZeneca plummeted following the FDA's rejection. Should you sell?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026